Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. (Q52868666)
Jump to navigation
Jump to search
scientific article published on 11 March 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. |
scientific article published on 11 March 2015 |
Statements
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. (English)
1 reference
James G Krueger
1 reference
Laura K Ferris
1 reference
Alan Menter
1 reference
Frank Wagner
1 reference
Alexander White
1 reference
Sudha Visvanathan
1 reference
Bojan Lalovic
1 reference
Stella Aslanyan
1 reference
Elaine E L Wang
1 reference
David Hall
1 reference
Alan Solinger
1 reference
Steven Padula
1 reference
Paul Scholl
1 reference
11 March 2015
1 reference
136
1 reference
1
1 reference
116-124.e7
1 reference
Identifiers
1 reference